CompletedPHASE1, PHASE2NCT00500812

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Studying Spinal cord injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Michael J. Fehlings, MD, PhD, FRCSC, FACS
Univestity Health Network, Toronto Western
Intervention
Cethrin(drug)
Enrollment
48 enrolled
Eligibility
16-70 years · All sexes
Timeline
20052009

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00500812 on ClinicalTrials.gov

Other trials for Spinal cord injury

Additional recruiting or active studies for the same condition.

See all trials for Spinal cord injury

← Back to all trials